Arteris, Inc.·4

Jun 3, 5:43 PM ET

Alpern Paul L 4

Research Summary

AI-generated summary

Updated

Arteris (AIP) VP & General Counsel Paul L. Alpern Exercises Options, Sells Shares

What Happened Paul L. Alpern, Vice President and General Counsel of Arteris, exercised stock options and sold shares on June 1, 2026. He acquired 4,000 shares at $0.56 ($2,240) and 2,500 shares at $9.28 ($23,200) through option exercises (total cost reported $25,440). On the same day he sold 11,504 shares at a weighted average price of $35.98 for $413,969 and 998 shares at a weighted average price of $36.39 for $36,317 (total sales proceeds ≈ $450,286). The Form 4 also reports two derivative disposals of 4,000 and 2,500 shares at $0.00 (reported as part of the option exercise mechanics).

Key Details

  • Transaction date: 2026-06-01; Form 4 filed 2026-06-03 (appears timely).
  • Option exercises acquired: 4,000 @ $0.56 ($2,240) and 2,500 @ $9.28 ($23,200).
  • Open-market sales: 11,504 @ weighted avg $35.98 (range $35.27–$36.26) and 998 @ weighted avg $36.39 (range $36.28–$36.56); total ≈ $450,286. (Footnotes F2/F3: weighted-average price ranges; issuer/staff can request per-trade breakdown.)
  • Zero-dollar derivative disposals: 4,000 and 2,500 shares reported at $0.00 (shown as derivative dispositions in the filing).
  • Shares owned after the transaction: not specified in the provided Form 4 excerpt.
  • Notable footnotes: trades were made pursuant to a 10b5-1 trading plan adopted Feb 23, 2026 (F1). Footnotes also reference incentive stock options and non-qualified stock options with stated vesting schedules (F4, F5).

Context The filing shows an option exercise paired with immediate open-market sales, a common pattern when insiders exercise and sell shares to cover exercise costs or taxes (the zero-dollar derivative disposals likely reflect those mechanics). Sales were executed under a pre-established 10b5-1 plan, which is intended to reduce the appearance of trading on insider information. This activity is a combination of option exercise (acquisition) and routine selling — not an explicit endorsement or negative signal about the company's prospects.